| 12351566 |
MEK inhibitors and therapeutic uses thereof |
Brett Matthew Hall, Peter King, Ruben Gerardus George Leenders, Anita WEGERT, Kevin Fowler +4 more |
2025-07-08 |
|
| 10766898 |
Therapeutic compound for pain and synthesis thereof |
Jacob Cornelis Russcher, Menno Cornelis Franciscus Monnee |
2020-09-08 |
$121,118,000 |
| 10358448 |
Therapeutic compounds for pain and synthesis thereof |
Jacob Cornelis Russcher, Menno Cornelis Franciscus Monnee |
2019-07-23 |
$66,924,000 |
| 10351566 |
Therapeutic compounds for pain and synthesis thereof |
Jacob Cornelis Russcher, Menno Cornelis Franciscus Monnee |
2019-07-16 |
$94,384,000 |
| 10351565 |
Therapeutic compounds for pain and synthesis thereof |
Jacob Cornelis Russcher, Menno Cornelis Franciscus Monnee |
2019-07-16 |
$94,384,000 |
| 10155762 |
Therapeutic compound for pain and synthesis thereof |
Jacob Cornelis Russcher, Menno Cornelis Franciscus Monnee |
2018-12-18 |
$201,471,000 |
| 10118900 |
Benzimidazole derivatives useful as CB-1 inverse agonists |
Mark J. Macielag, Rui Zhang, Yue-Mei Zhang, Bin Zhu, Michael H. Parker +3 more |
2018-11-06 |
$103,036,000 |
| 10040795 |
Therapeutic compounds for pain and synthesis thereof |
Jacob Cornelis Russcher, Menno Cornelis Franciscus Monnee |
2018-08-07 |
$78,997,000 |
| 10040796 |
Therapeutic compounds for pain and synthesis thereof |
Jacob Cornelis Russcher, Menno Cornelis Franciscus Monnee |
2018-08-07 |
$78,997,000 |
| 10040797 |
Therapeutic compounds and synthesis |
Jacob Cornelis Russcher, Menno Cornelis Franciscus Monnee |
2018-08-07 |
$78,997,000 |
| 9994572 |
Therapeutic compounds for pain and synthesis thereof |
Jacob Cornelis Russcher, Menno Cornelis Franciscus Monnee |
2018-06-12 |
$96,711,000 |
| 9732061 |
Cinnoline derivatives useful as CB-1 receptor inverse agonists |
Mark J. Macielag, Yue-Mei Zhang, Michael N. Greco, Donald Ludovici, Michael H. Parker |
2017-08-15 |
$72,986,000 |
| 9682955 |
Quinazoline derivatives useful as CB-1 inverse agonists |
Mark J. Macielag, Yue-Mei Zhang, Michael N. Greco |
2017-06-20 |
$117,780,000 |
| 9682940 |
Indazole derivatives useful as CB-1 inverse agonists |
Mark J. Macielag, Rui Zhang, Michael H. Parker, Michael N. Greco |
2017-06-20 |
$117,780,000 |
| 9464055 |
Quinoline derivatives useful as CB-1 inverse agonists |
Mark J. Macielag, Michael N. Greco, Yue-Mei Zhang, Christopher A. Teleha |
2016-10-11 |
$160,293,000 |
| 9266835 |
Quinoline derivatives useful as CB-1 inverse agonists |
Mark J. Macielag, Michael N. Greco, Yue-Mei Zhang, Christopher A. Teleha |
2016-02-23 |
$58,494,000 |
| 8846655 |
4-substituted-2-phenoxy-phenylamine delta opioid receptor modulators |
Steven J. Coats, Haiyan Bian, Chaozhong Cai, Li Liu, Mark J. Macielag +4 more |
2014-09-30 |
$69,305,000 |
| 8686152 |
4,4-disubstituted piperidine derivatives useful as inhibitors of dipeptidyl peptidase-1 (DPP-1) |
Renee Louise Desjarlais, Yifang Huang, Michael H. Parker, Dennis J. Hlasta |
2014-04-01 |
$99,485,000 |
| 8685990 |
Pyrimidine compounds as delta opioid receptor modulators |
Steven J. Coats, Haiyan Bian, Peter J. Connolly, Gilles Bignan, Chaozhong Cai +8 more |
2014-04-01 |
$99,485,000 |
| 8513271 |
Pyrimidine compounds as delta opioid receptor modulators |
Steven J. Coats, Haiyan Bian, Peter J. Connolly, Gilles Bignan, Chaozhong Cai +8 more |
2013-08-20 |
$67,183,000 |
| 7652005 |
Tricyclic δ-opioid modulators |
Steve J. Coats, Scott L. Dax, Li Liu, Mark McDonnell, James J. McNally |
2010-01-26 |
$104,981,000 |
| 7589104 |
Tricyclic-bridged piperidinyline derivatives as §-opioid modulators |
John R. Carson, Scott L. Dax, Li Liu, Mark McDonnell, James J. McNally |
2009-09-15 |
$145,140,000 |
| 7582650 |
Tricyclic opioid modulators |
Li Liu, Mark McDonnell, Jim McNally |
2009-09-01 |
$299,658,000 |
| 7553850 |
Tricyclic-bridged piperidinylidene derivatives as δ-opioid modulators |
Scott L. Dax, Li Liu, Mark McDonnell, James J. McNally |
2009-06-30 |
$388,377,000 |
| 7439239 |
Tricyclic δ- opioid modulators |
Steve J. Coats, Scott L. Dax, Li Liu, Mark McDonnell, James J. McNally |
2008-10-21 |
$362,750,000 |
